Formulation and characterization of nanoemulsion-based drug delivery system of risperidone.
Risperidone nanoemulsion (NE) and mucoadhesive NE formulations were successfully prepared by the spontaneous emulsification method (titration method) using Capmul MCM as the oily phase on the basis of solubility studies. The NE formulation containing 8% oil, 44% S(mix), 48% (wt/wt) aqueous phase that displayed an optical transparency of 99.82%, globule size of 15.5 +/- 2.12 nm, and polydispersity of 0.172 +/- 0.02 was selected for the incorporation of mucoadhesive components. The mucoadhesive formulation that contained 0.5% by weight of chitosan displayed highest diffusion coefficient that followed Higuchi model was free from nasal ciliotoxicity and stable for 3 months.
Kumar
Mukesh
M
Department of Pharmaceutics Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India.
Pathak
Kamla
K
Misra
Ambikanandan
A
D000281:Administration, Intranasal; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D001812:Blood-Brain Barrier / Q000378:metabolism; D048271:Chitosan / Q000737:chemistry; D004058:Diffusion; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D004655:Emulsions; D066298:In Vitro Techniques; D053758:Nanoparticles; D009297:Nasal Mucosa / Q000187:drug effects / Q000473:pathology; D051381:Rats; D018967:Risperidone / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D012756:Sheep; D012995:Solubility; D014018:Tissue Distribution
D014150:Antipsychotic Agents; D004655:Emulsions; D048271:Chitosan; D018967:Risperidone